๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2024-08-29

Surgery and Reducing Ionizing Radiation of the Unknown Primary (NCT06578871)

Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma: Reducing Ionizing Radiation (SUPERIOR): A Randomized Trial

๐ŸŸก Not Yet Recruiting Phase2 ๐Ÿฉบ Clinical Procedure Protocol Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

About 3% of people with head and neck cancer have cancer in their lymph nodes, but doctors are unable to find the primary tumour. This situation has become more common due to human papillomavirus (HPV), a virus linked to certain cancers. Generally, patients with HPV-related cancers have a good outlook, with around 90% surviving for at least five years. Recent advancements in medical technology, such as advanced imaging and specialized surgeries, have significantly improved doctors' ability to find these hidden tumours. These techniques can locate the primary tumour in 70-80% of cases. If the tumour remains undetected, it could be very small or potentially eliminated by the body's immune system. The best way to treat this type of cancer is still debated. Current treatment options include surgery to remove lymph nodes or radiation therapy. There is no clear agreement on which areas should receive radiation. Often, surgery is performed on one side of the throat to try and locate the tumour's origin. Researchers are exploring ways to minimize the harmful side effects of treatment. Some studies suggest that surgery alone might be sufficient for patients with small tumours in their neck, but more research is needed. Another important question is whether radiation needs to cover the entire throat area. Recent findings suggest that omitting radiation from some areas might reduce side effects such as difficulty swallowing and dry mouth. The SUPERIOR trial aims to investigate whether reducing the amount of radiation can still be effective and improve patients' quality of life. The study also examines whether surgery alone is adequate for certain patients with HPV-related cancers.

Who can join: Review the eligibility criteria below.

Location: Royal Adelaide Hospital โ€” Adelaide, South Australia

Age range: 18 Years

๐Ÿงช Interventions in This Study

  • Intensity Modulated Radiotherapy (IMRT) to Mucosa at Risk (RADIATION)
  • Surgical Intervention (PROCEDURE)
  • Intensity Modulated Radiotherapy (IMRT) to Ipsilateral Neck (RADIATION)

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (3 Sites)

  • Royal Adelaide Hospital โ€” Adelaide, South Australia
  • Flinders Medical Centre โ€” Adelaide, South Australia
  • London Health Sciences Centre โ€” London, Ontario

๐Ÿ“ž Contact the Study Coordinator

Phone: (519) 685-8500

Email: halema.khan@lhsc.on.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—